AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Refractory Autoimmune Diseases

A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases NCT07333118EARLY Phase 11 site📍 Shanghai Grit Biotechnology · Tests: GT801 Injection CAR-T Therapy for Refractory Autoimmune Diseases NCT07059169NA1 site📍 Wuhan LiangZou · Tests: JY231 (JY231 injection) A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus NCT07444307Phase 13 sites📍 Hefei📍 Wuhan📍 Beijing Hangzhou Qihan Biotech Co., Ltd. · Tests: QT-019B Cell Injection An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease NCT06379646NA1 site📍 Shanghai China Immunotech (Beijing) Biotechnology Co., Ltd. · Tests: YTS109 Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE NCT07233642Phase 11 site📍 Hangzhou The Children's Hospital of Zhejiang University School of Me… · Tests: CD19 CAR-T cells In Vivo CAR-T for Refractory Graves' Disease NCT07333677EARLY Phase 11 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: In Vivo CAR-T Therapy CAR-T Cells Therapy for Patients With Autoimmune Diseases NCT07052565NA1 site📍 Hefei Anhui Provincial Hospital · Tests: Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases NCT07470151NA1 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: EVM18001 Injection Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases NCT07558850NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: anti-CD19/BCMA-UCAR-T cells Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) NCT06350110Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: CD19- BCMA CAR-T cells CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases NCT06941129Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: UCAR T-cell Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases NCT06939166EARLY Phase 11 site📍 Tianjin Tianjin Huanhu Hospital · Tests: UCAR T-cell NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis NCT06676631Phase 11 site📍 Guangzhou Guangdong Provincial People's Hospital · Tests: NK 010 or NK042, Rituximab Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases NCT06828042Phase 1, Phase 21 site📍 Beijing Peking University Third Hospital · Tests: anti-CD19 CAR T cell therapy Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases NCT06685042Phase 1, Phase 21 site📍 Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: CAR T cell GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103) NCT07058298EARLY Phase 11 site📍 Wuhan Daishi Tian · Tests: GC012F injection CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases NCT07315087Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: QT-019C A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases NCT07275736EARLY Phase 11 site📍 Beijing Juventas Cell Therapy Ltd. · Tests: CNCT19 cell injection An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases NCT07174843EARLY Phase 11 site📍 Shanghai Shanghai Cell Therapy Group Co.,Ltd · Tests: CD19/CD22/BCMA CAR-T cells(BZE2204) BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008Phase 21 site📍 Beijing Peking University People's Hospital · Tests: BCMA-CD19 CAR-T therapy A Clinical Study of the Safety, Tolerability and Preliminary Efficacy of CD19/BCMA-targeted CAR-T Therapy in Refractory Autoimmune Diseases NCT07490951NA3 sites📍 Wuhan📍 Wuhan📍 Wuhan Liang Zou · Tests: CD19/BCMA-targeted CAR-T lentiviral vector drug Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia NCT06826430Phase 11 site📍 Beijing Juventas Cell Therapy Ltd. · Tests: Inaticabtagene autoleucel Injection Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases NCT07184450Phase 11 site📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: BCMA/CD70-targetd CAR-T A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis NCT07570862Phase 212 sites📍 Beverly Hills📍 Fontana📍 Fullerton Fate Therapeutics · Tests: FT819 CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases NCT06680388EARLY Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Drug:CD19 CAR-T Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus NCT06789107Phase 12 sites📍 Hangzhou📍 Hangzhou Mao Jianhua · Tests: Blinatumomab 9ug A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases NCT06978647Phase 11 site📍 Beijing China Immunotech (Beijing) Biotechnology Co., Ltd. · Tests: YTS109 cell Alnuctamab for Refractory SLE (LATTE Study) NCT07219563Phase 11 site📍 New York Icahn School of Medicine at Mount Sinai · Tests: Alnuctamab Study of CD19 CAR-T Therapy for Refractory SLE NCT07403097Phase 11 site📍 Chongqing Chongqing Precision Biotech Co., Ltd · Tests: PTOC1 BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases NCT06787989Phase 11 site📍 Chengdu iCell Gene Therapeutics · Tests: BCMA-CD19 cCAR T cells
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy